Theratechnologies Q1 EPS $(0.10) Beats $(0.12) Estimate, Sales $16.25M Miss $20.10M Estimate
Portfolio Pulse from Benzinga Newsdesk
Theratechnologies (NASDAQ:THTX) reported Q1 EPS of $(0.10), beating the $(0.12) estimate, but missed sales estimates with $16.25M against the expected $20.10M. This represents a 77.27% increase in EPS and an 18.39% decrease in sales from the same period last year.

April 10, 2024 | 11:33 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Theratechnologies reported a mixed Q1 with an EPS beat but a miss on sales estimates, showing a significant improvement in EPS but a decline in sales from the previous year.
The EPS beat might provide some positive sentiment among investors due to the significant improvement over last year's losses. However, the miss on sales estimates and the year-over-year decline in sales could raise concerns about the company's revenue growth and market demand for its products. The mixed results make the short-term impact on the stock price uncertain, hence a neutral score.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100